AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10687982
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination and transrectal ultrasonography at PSA 0 to 4.0 ng/ml
Trial: 10687982
Drug: PSA 2
RxNorm normalized name: Prednisolone Sodium Phosphate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSA 2 to 4 ng/ml
Trial: 10687982
Drug: PSA 0
RxNorm normalized name: Prednisolone Sodium Acetate 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA 0 to 4 ng/ml
Trial: 9322122
Drug: Serum cytokeratin
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum cytokeratin 19 levels > 2 ng/mL in pancreatic duct cell carcinoma
Trial: 8195846
Drug: Comparative agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative agents (ampicillin, amoxicillin, cephalosporins, erythromycin, doxycycline, chloramphenicol)
Trial: 3026016
Drug: sulbactam/ampicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulbactam/ampicillin (50 mg/kg per day, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Trial: 3026016
Drug: sulbactam/penicillin (1:1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulbactam/penicillin (1:1.2 or 1:1.8 ratio, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Trial: 29169916
Drug: Lissamine green
RxNorm normalized name: LISSAMINE GREEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lissamine green solution (GreenGlo)
Trial: 29169916
Drug: Lissamine green
RxNorm normalized name: LISSAMINE GREEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lissamine green solution (Lissaver)
Trial: 29169916
Drug: OPGreen solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPGreen solution
Trial: 22834681
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% (30 ml)
Trial: 21163117
Drug: Capecitabine 825
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m² twice daily plus weekly docetaxel 30 mg/m² on days 1 and 8 every 21 days
Trial: 15928658
Drug: Capecitabine 500
RxNorm normalized name: capecitabine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 500 mg m(‐2) b.i.d.(‐1)
Trial: 15928658
Drug: Capecitabine 625
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 625 mg m(‐2) b.i.d.(‐1)
Trial: 15497659
Drug: Pegvisomant 10
RxNorm normalized name: pegvisomant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant 10 mg/day
Trial: 15497659
Drug: Pegvisomant 15
RxNorm normalized name: pegvisomant 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant 15 mg/day
Trial: 15497659
Drug: Pegvisomant 20
RxNorm normalized name: pegvisomant 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant 20 mg/day
Trial: 8737522
Drug: Thromboembolism prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboembolism prophylaxis with acenocoumarol during radiation therapy
Trial: 8737522
Drug: LMW heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW heparin during radiation therapy
Trial: 8737522
Drug: Acenocoumarol during
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol during radiation therapy
Trial: 2065389
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phentolamine (20‐30 mg/day) and angelicini (150‐450 mg/day)
Trial: 2065389
Drug: Conventional supporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional supporting therapy
Trial: 14513774
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron preparation
Trial: 22818729
Drug: Variety of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variety of vegetables (200 g of each of broccoli, carrots, and snap peas)
Trial: 22818729
Drug: Single vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vegetable servings (600 g of broccoli, carrots, or snap peas)
Trial: 12149599
Drug: Acarbose (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (2 x 50 mg)
Trial: 10215302
Drug: Chronic estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic estrogen replacement therapy
Trial: 7793735
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg IV over 30 minutes, followed by 1 mg/kg/hr infusion for 12 hours)
Trial: 31280967
Drug: Risankizumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (150 mg subcutaneously at weeks 0 and 4)
Trial: 31280967
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter)
Trial: 31280967
Drug: Risankizumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (150 mg)
Trial: 20443719
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol gel (1 mg)
Trial: 19888035
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol with daily medroxyprogesterone acetate
Trial: 17590369
Drug: 1 injection
RxNorm normalized name: vitamin K1 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of 1ml Sodium Hyaluronidate (Sinovial)
Trial: 17590369
Drug: 2 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 injections of 1ml Sodium Hyaluronidate (Sinovial)
Trial: 17590369
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of 1ml Sodium Hyaluronidate (Sinovial)
Trial: 3318539
Drug: alpha‐fluoromethyl histidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐fluoromethyl histidine, 100 mg twice daily for 3 weeks
Trial: 26831168
Drug: 62.7 ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.7 ± 3.1 g of IgG IV in 2.6 ± 0.3 L of plasma within 6 h after birth
Trial: 26831168
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L of high quality colostrum within 12 h of birth
Trial: 25651956
Drug: Intraperitoneal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal ropivacaine (5 mL 1 % Naropin(®))
Trial: 30623534
Drug: Saline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (5 mL)
Trial: 21910713
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg kg⁻¹ at weeks 0, 2, 6, 14 and 22
Trial: 21910713
Drug: Methotrexate 15
RxNorm normalized name: methotrexate 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 mg weekly (increased to 20 mg weekly at week 6 if PASI response < 25%)
Trial: 12548587
Drug: Bisphosphonate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate therapy (clodronate or pamidronate)
Trial: 12005179
Drug: Intravenous bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bisphosphonates
Trial: 9754791
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (200 mg)
Trial: 9754791
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (100 mg)
Trial: 9754791
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (50 mg)
Trial: 8549083
Drug: Selenium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Trial: 8549083
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Trial: 28368437
Drug: PM01183 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 at 7.0 mg flat dose every 3 weeks (q3wk)
Trial: 28368437
Drug: Topotecan (days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (days 1-5 q3wk or weekly q4wk)
Trial: 23966309
Drug: Idraparinux (fixed-dose)
RxNorm normalized name: Humalog Mix
DrugBank: Idraparinux (DB06406)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idraparinux (fixed-dose)
Trial: 23966309
Drug: Conventional anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticoagulation (dose-adjusted vitamin K antagonists)
Trial: 21417594
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (OCP) plus myo-inositol (MI) 4 g/die for 12 months
Trial: 21417594
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (OCP) plus myo-inositol (MI)
Trial: 21417594
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (OCP) alone
Trial: 18802361
Drug: Cluster schedule
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster schedule of specific immunotherapy (6-week duration)
Trial: 18802361
Drug: Conventional schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional schedule of specific immunotherapy (14-week duration)
Trial: 15250225
Drug: Bronchofiberscopic (BF)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchofiberscopic (BF) injection of 4% lidocaine
Trial: 11526793
Drug: Inpatient services
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient services and drugs administration
Trial: 28342741
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen cream
Trial: 23663021
Drug: Educational preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational preparation for supervision and systematic reflection on supervision.
Trial: 19747429
Drug: Azelastine 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 0.15% nasal spray (2 sprays/nostril once daily)
Trial: 22287431
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 sprays/nostril once daily)
Trial: 19297072
Drug: Pre-operative treatment
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative treatment with triptorelin depot (GnRH-a)
Trial: 9669750
Drug: Dalteparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (5000 antifactor Xa units subcutaneously once daily for 35 days)
Trial: 9669750
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 28 days after 7 days of dalteparin
Trial: 3349555
Drug: Edrophonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.25 mg.kg‐1 and 0.3 mg.kg‐1
Trial: 3349555
Drug: Edrophonium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.05 to 0.2 mg.kg‐1
Trial: 16792454
Drug: Somatostatin (SMT)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMT) 250 mg/h
Trial: 16792454
Drug: Somatostatin (SMT)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SMT) 500 mg/h
Trial: 14557107
Drug: Sensitivity analysis
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitivity analysis for treatment comparisons
Trial: 9024009
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (10 micrograms/kg)
Trial: 9181154
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (30 micrograms/kg) with PCA
Trial: 25636291
Drug: Xinjingjie mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinjingjie mouthrinse (5 mL, 4 times daily during radiotherapy)
Trial: 22373953
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (400mg) daily
Trial: 22373953
Drug: Ground fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground fish (529±109mg) daily
Trial: 15742593
Drug: Preoperative intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Trial: 15742593
Drug: Postoperative intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Trial: 14569937
Drug: R-CHOP chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP chemotherapy
Trial: 8636761
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg TNF, IFN (0.2 mg), melphalan (10 mg/L limb volume)
Trial: 8636761
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg TNF, IFN (0.2 mg), melphalan (10 mg/L limb volume)
Trial: 8636761
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg TNF
Trial: 8636761
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg TNF
Trial: 27604504
Drug: Optimal supportive
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal supportive care (OSC) plus whole brain radiotherapy (WBRT) (20 Gy in five daily fractions)
Trial: 15492322
Drug: Fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 20 mg
Trial: 3113245
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 micrograms four times daily for seven days)
Trial: 31407414
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (IMIQ)
Trial: 31407414
Drug: Diclofenac 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 3% gel (DIC)
Trial: 23889940
Drug: MgSO(4) 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO(4) 70 mg/kg
Trial: 19231315
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 to 40 mg/day)
Trial: 12812657
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg and letrozole (2.5 mg) orally q.d. for 8 weeks
Trial: 12812657
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg and exemestane (25 mg) orally q.d. for 8 weeks
Trial: 11064501
Drug: Triple antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiretroviral therapy
Trial: 10997396
Drug: Double antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double antiretroviral therapy
Trial: 10997396
Drug: Both double
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both double and triple therapies
Trial: 8159300
Drug: Cyclosporin (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (CsA) 5 mg/kg/day in adults, 6 mg/kg/day in children for 9 months, tapered off by 25% every month until complete discontinuation at month 12
Trial: 8159300
Drug: Cyclophosphamide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 2.5 mg/kg/day for 8 weeks
Trial: 29579042
Drug: Mesalamine treatment
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine treatment (multiple doses over 6 weeks)
Trial: 25049132
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei subsp paracasei L. casei W8 (10^9 CFU)
Trial: 25049132
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei subsp paracasei L. casei W8 (10^10 CFU)
Trial: 17610346
Drug: Self-management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management of oral anticoagulant therapy (including a teaching program for self-management followed by 6 months of independent self-management)
Trial: 6828828
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation programme including diet therapy
Trial: 22607165
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control (treatment as usual)
Trial: 24060951
Drug: Synbiotics preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics preparation for one month
Trial: 19101098
Drug: Methadone dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone dose increase (100mg/day) with split contingency
Trial: 19101098
Drug: Methadone dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone dose increase (70mg/day) with split contingency
Trial: 19101098
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment during 5-week baseline
Trial: 18360012
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg/day)
Trial: 17345784
Drug: Control (Rosiglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Rosiglitazone 4 mg/day)
Trial: 14659863
Drug: GP IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP IIb/IIIa inhibitors (abciximab) administered intravenously, along with heparin and aspirin during failed thrombolysis or after effective thrombolysis due to pain recurrence and ST segment elevation.
Trial: 14659863
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered with full dose of rtpA (100 mg) and standard heparin treatment and aspirin during failed thrombolysis or after effective thrombolysis due to pain recurrence and ST segment elevation.
Trial: 14659863
Drug: GP IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP IIb/IIIa inhibitors (abciximab)
Trial: 17154747
Drug: Integrative Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative Behavioral Couple Therapy (IBCT)
Trial: 6485854
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg glucagon/kg body weight intramuscularly before attempts at reduction
Trial: 31671592
Drug: Novel smartphone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel smartphone application accessed weekly from week 1 to week 6
Trial: 26687391
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m², once every 21 days) plus best supportive care
Trial: 25180609
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L polyethylene glycol plus ascorbate (PEG+Asc)
Trial: 21306085
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri supplementation (containing L. reuteri, ATCC 55730 and ATCC PTA 5289) for 12 weeks
Trial: 17437874
Drug: 10% propolis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% propolis solution
Trial: 17437874
Drug: 20% propolis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% propolis solution
Trial: 17437874
Drug: Hank's Balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hank's Balanced Salt Solution
Trial: 11434589
Drug: Oral PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PEG 4000 treatment
Trial: 9757919
Drug: pHi-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pHi-guided therapy
Trial: 8141282
Drug: Lower body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower body negative pressure (LBNP) during insulin clamp
Trial: 8141282
Drug: Control study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control study (no LBNP) during insulin clamp
Trial: 3513564
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol
Trial: 30260780
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy added to sedation
Trial: 30260780
Drug: No music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No music treatment (control group)